Literature DB >> 21643739

Serum interleukin-33 levels in patients with gastric cancer.

Pinghu Sun1, Qiwen Ben, Shuiping Tu, Wenjie Dong, Xiaoguang Qi, Yunlin Wu.   

Abstract

BACKGROUND: Interleukin-33 (IL-33) is a novel member of the IL-1 family of cytokines, and it is closely related to IL-18, one of the best characterized members of the IL-1 family. It's been demonstrated that elevated levels of IL-18 are involved in a wide variety of tumors, especially in gastric cancer. AIMS: The purpose of this study was to determine the correlations between serum IL-33 levels and the clinicopathologic features in gastric cancer patients.
METHODS: Serum samples were collected from 68 patients with gastric cancer and 57 controls. Serum IL-33 levels were measured by ELISA. Classical tumor markers of CEA and CA19-9 levels were routinely detected by chemiluminescence immunoassay. Western blot analysis was used to detect IL-33 expression in gastric cancer tissue samples and cell lines. The relationship between serum levels of IL-33 and clinical characteristics in patients was analyzed.
RESULTS: IL-33 levels in the serum of gastric cancer patients were significantly elevated in comparison with that of healthy volunteers. Furthermore, higher serum levels of IL-33 in gastric cancer patients were found to correlate with several poor prognostic factors like depth of invasion, distant metastasis and advanced stage (stage III/IV). On the other hand, serum IL-33 levels did not correlate with CEA and CA19-9. The expression of IL-33 protein was upregulated in carcinoma tissues in comparison with matched normal tissues, and no statistically significant difference was found between the four gastric cancer cell lines and human gastric epithelial cell line GES-1.
CONCLUSIONS: Serum IL-33 may be a useful biomarker for predicting the prognosis of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21643739     DOI: 10.1007/s10620-011-1760-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex.

Authors:  Alissa A Chackerian; Elizabeth R Oldham; Erin E Murphy; Jochen Schmitz; Stefan Pflanz; Robert A Kastelein
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

2.  Diagnostic role of serum interleukin-18 in gastric cancer patients.

Authors:  Duangporn Thong-Ngam; Pisit Tangkijvanich; Rungsun Lerknimitr; Varocha Mahachai; Apiradee Theamboonlers; Yong Poovorawan
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

3.  Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production.

Authors:  Yeon-Sook Choi; Hyun-Jung Choi; Jeong-Ki Min; Bo-Jeong Pyun; Yong-Sun Maeng; Hongryeol Park; Jihye Kim; Young-Myeong Kim; Young-Guen Kwon
Journal:  Blood       Date:  2009-08-06       Impact factor: 22.113

4.  Enhanced IL-18 expression in common skin tumors.

Authors:  H Park; D Byun; T S Kim; Y I Kim; J S Kang; E S Hahm; S H Kim; W J Lee; H K Song; D Y Yoon; C J Kang; C Lee; D Houh; H Kim; B Cho; Y Kim; Y H Yang; K H Min; D H Cho
Journal:  Immunol Lett       Date:  2001-12-03       Impact factor: 3.685

Review 5.  The IL-33/ST2 pathway: therapeutic target and novel biomarker.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

6.  Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches.

Authors:  Sojung Lee; Jungwoo Kang; Minchul Cho; Eunhee Seo; Heesook Choi; Eunjin Kim; Junghee Kim; Heejong Kim; Gum Yong Kang; Kwang Pyo Kim; Young-Ho Park; Dae-Yeul Yu; Young Na Yum; Sue-Nie Park; Do-Young Yoon
Journal:  Int J Oncol       Date:  2009-01       Impact factor: 5.650

7.  IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells.

Authors:  Shafaqat Ali; Michael Huber; Christian Kollewe; Stephan C Bischoff; Werner Falk; Michael U Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-14       Impact factor: 11.205

8.  IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers.

Authors:  Mohammad Reza Haghshenas; Seyed Vahid Hosseini; Mahmoud Mahmoudi; Mehdi Saberi-Firozi; Shirin Farjadian; Abbas Ghaderi
Journal:  J Gastroenterol Hepatol       Date:  2009-06       Impact factor: 4.029

Review 9.  Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist.

Authors:  C A Dinarello
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

10.  Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix.

Authors:  A Sharma; M Rajappa; A Saxena; M Sharma
Journal:  Int J Gynecol Cancer       Date:  2007-03-05       Impact factor: 3.437

View more
  55 in total

Review 1.  Role of the IL-33/ST2 receptor axis in ovarian cancer progression.

Authors:  Ning Liu; Jintong Chen; Yinghua Zhao; Mingyue Zhang; Li Piao; Siqing Wang; Ying Yue
Journal:  Oncol Lett       Date:  2021-04-29       Impact factor: 2.967

Review 2.  The route to pathologies in chronic inflammatory diseases characterized by T helper type 2 immune cells.

Authors:  K Jovanovic; M Siebeck; R Gropp
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

Review 3.  Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.

Authors:  Binfeng Lu; Min Yang; Qingqing Wang
Journal:  J Mol Med (Berl)       Date:  2016-02-27       Impact factor: 4.599

4.  Decreased ST2 expression is associated with gastric cancer progression and pathogenesis.

Authors:  Feihu Bai; Fangyun Ba; Yanjie You; Yaning Feng; Wei Tao; Chuanxia Wu; Mengna Jiu; Yongzhan Nie
Journal:  Oncol Lett       Date:  2019-04-05       Impact factor: 2.967

5.  Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients.

Authors:  Wenwei Hu; Xiaodong Li; Qing Li; Yan Tan; Bin Xu; Quanqin Xie; Xu Deng; Binfeng Lu; Jingting Jiang; Changping Wu
Journal:  Pathol Oncol Res       Date:  2016-12-20       Impact factor: 3.201

6.  Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways.

Authors:  Xiaoguang Tong; Mark Barbour; Kezuo Hou; Chao Gao; Shuang Cao; Jingli Zheng; Yang Zhao; Rong Mu; Hui-Rong Jiang
Journal:  Mol Oncol       Date:  2015-09-09       Impact factor: 6.603

7.  Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer.

Authors:  Donye Dominguez; Cong Ye; Zhe Geng; Siqi Chen; Jie Fan; Lei Qin; Alan Long; Long Wang; Zhuoli Zhang; Yi Zhang; Deyu Fang; Timothy M Kuzel; Bin Zhang
Journal:  J Immunol       Date:  2016-12-23       Impact factor: 5.422

8.  IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis.

Authors:  Yu Zhang; Celestia Davis; Sapana Shah; Daniel Hughes; James C Ryan; Diego Altomare; Maria Marjorette O Peña
Journal:  Mol Carcinog       Date:  2016-04-27       Impact factor: 4.784

9.  Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells.

Authors:  Peng Xiao; Xiaopeng Wan; Bijun Cui; Yang Liu; Chenyang Qiu; Jiabing Rong; Mingzhu Zheng; Yinjing Song; Luoquan Chen; Jia He; Qinchun Tan; Xiaojia Wang; Xiying Shao; Yuhua Liu; Xuetao Cao; Qingqing Wang
Journal:  Oncoimmunology       Date:  2015-06-24       Impact factor: 8.110

10.  High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma.

Authors:  Dominik Bergis; Valentin Kassis; Annika Ranglack; Verena Koeberle; Albrecht Piiper; Bernd Kronenberger; Stefan Zeuzem; Oliver Waidmann; Heinfried H Radeke
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.